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Accurate quantitation of mitochondrial DNA content in human blastocysts reveals 
unvarying levels regardless of embryo ploidy, age, and implantation potential.   
 ABSTRACT 
 
Objective: To accurately determine mitochondrial DNA (mtDNA) levels in human 
blastocysts. 
 
Design: Retrospective analysis. 
 
Setting: PGS laboratory of IVF clinic. 
 
Patient(s): 1396 embryos derived from 259 patients. 
 
Intervention(s): Blastocyst-derived trophectoderm biopsies were tested by NGS and 
qPCR. 
 
Main Outcome Measure(s): For each sample the mtDNA value was divided by the 
nuclear DNA (nDNA) value and the result was further subjected to mathematical 
analysis tailored to the genetic makeup of the source embryo.  
 
Result(s): On average the mathematical correction factor changed the conventionally 
determined mtDNA score of a given blastocyst via NGS by 1.43% +/-1.59% (N=1396), 
with maximal adjustments of 17.42%, and via qPCR by 1.33% +/-8.08% (N=150), with 
maximal adjustments of 50.00%. Levels of mtDNA in euploid and aneuploid embryos 
showed a statistically insignificant difference by NGS (euploids N=775, aneuploids 
N=621) and by qPCR (euploids N=100, aneuploids N=50). Blastocysts derived from 
younger or older patients had comparable mtDNA levels by NGS ( ?ǇŽƵŶŐ ?ĂŐĞŐƌŽƵƉ
N=874 ? ?ĂĚǀĂŶĐĞĚ ? age group N=514) and by qPCR ( ?ǇŽƵŶŐ ?ĂŐĞŐƌŽƵƉEA? ? ? ? ?ĂĚǀĂŶĐĞĚ ? 
age group N=58). Viable blastocysts did not contain significantly different mtDNA levels 
compared to unviable blastocysts when analyzed by NGS (implanted N=101, non-
implanted N=140) and by qPCR (implanted N=49, non-implanted N=51). 
 Conclusion(s): We recommend implementation of the correction factor calculation to 
laboratories evaluating mtDNA levels in embryos by NGS or qPCR. When applied to our 
in-house data, the calculation reveals that overall levels of mtDNA are largely equal 
between blastocysts stratified by ploidy, age, or implantation potential. 
 
Key Words: embryonic mitochondria; blastocyst mtDNA; correction factor; PGS/PGD; 
IVF biomarker  
  
 INTRODUCTION  
 
Human cells contain anywhere from 100 to 150,000+ copies of the mitochondrial 
DNA (mtDNA) molecules depending on cell type (1, 2), and several conditions correlate 
with changes in mtDNA copy number including aging, myopathies, neuropathies, 
diabetes, and cancer (3). In human embryos, recent studies have investigated amounts 
of mtDNA, generally describing a correlation of high mtDNA levĞůƐǁŝƚŚĂ ?ƐƚƌĞƐƐĞĚ ?ƐƚĂƚĞ
(4-6). Conditions that deviate from the steady state such as aneuploidy, advanced 
maternal age, or chemically induced-stress tend to associate with higher mtDNA 
content. Of clinical relevance, such reports suggested that embryos with mtDNA levels 
above the norm showed significantly poor frequency of pregnancy when transferred (4, 
5).  
The described observations are in line ǁŝƚŚƚŚĞ ?YƵŝĞƚŵďƌǇŽ,ǇƉŽƚŚĞƐŝƐ ? ?ǁŚŝĐŚ
postulates that under ideal circumstances embryos are engaged in low metabolic 
activity (7). Elevated mtDNA levels and by extension increased ATP production could be 
a compensatory mechanism providing distressed embryos with more chemical energy to 
overcome adverse conditions. Therefore, in the case of euploid embryos being chosen 
for transfer, sub-optimal intrinsic or environmental factors could elicit higher levels of 
mtDNA. Consequently, mtDNA content has been proposed as a biomarker for embryo 
viability (4, 5). 
Crucial to such investigations are methods that permit precise measurements of 
mtDNA levels. In situ hybridization has previously been used (8), probing for a region of 
the mtDNA sequence, but this method has not been widely adopted possibly due to 
laboriousness and difficulty in interpreting results. More commonly employed 
technologies are quantitative real-time polymerase chain reaction (qPCR) and 
sequencing platforms, especially next generation sequencing (NGS). Both methods yield 
one value for mtDNA and one value for nuclear DNA (nDNA) quantity, and the ratio of 
mtDNA to nDNA is the principal mode to assess mtDNA quantity per cell (9). Crucially, 
using nDNA values for normalization assumes that the composition of nDNA is equal 
across samples. 
When nDNA composition varies across samples, such as in cancer, the disparities 
must be accounted for. For such a purpose the use of a mathematical correction factor 
has been proposed in mtDNA studies of cancer (10). The correction factor takes into 
account characteristics of tumor biology that affect nDNA values such as genetic 
abnormalities of cancerous cells and tumor cell heterogeneity due to stroma and 
immune infiltrates (10).  Only after such a mathematical adjustment are side-by-side 
comparisons of mtDNA levels across tumor samples appropriate. To our knowledge, 
such a correction factor has not been employed in studies of mtDNA levels in embryos.  
In order to determine mtDNA levels in blastocysts accurately, we developed a 
mathematical formula adapted to the nuances of human embryology, and derived a 
correction factor that accounts for genomic variation due to embryo gender and ploidy. 
We then undertook an analysis of mtDNA levels in biopsies from human blastocysts 
derived from patients with infertility at the Zouves Fertility Center (ZFC). In contrast to 
previous reports, our corrected values show no statistically significant differences in 








This study was a retrospective analysis of de-identified NGS workflow data and WGA 
product from patients consenting to preimplantation genetic screening during routine 
IVF procedures. It is exempt from IRB review by the U.S Department if Health & Human 
Services under 45 CFR 46.101(b)(4). 
 
 
Embryo Processing  
 
IVF and culturing of embryos took place at ZFC using standard techniques. Briefly, 
fertilization was accomplished using intracytoplasmic sperm injection and zygotes were 
cultured for 5 to 7 days in either G1/G2 Plus medium  (Vitrolife) or GTL (Vitrolife) in 5.5% 
CO2, 5.5% O2 balance N2 at 37 C in a humidified atmosphere. Five to ten-cell 
trophectoderm biopsies were collected from blastocyst stage embryos and stored at -80 
degrees Celsius until further processing. WGA on each biopsy was performed using the 
Sureplex system (Rubicon) and followed by NGS with the MiSeq sequencer (Illumina), as 
per the standard Veriseq protocol (Illumina). Embryo ploidy was assessed with the 
Bluefuse Multi Software (BMS) (Illumina). We investigated mtDNA content in a total of 
1396 embryos, 241 of which were selected for frozen embryo transfer (225 as single 
embryos and 16 as paired siblings). 
 
 
Determination of mtDNA content by NGS 
 
For each sample, MiSeq Reporter Software (MCS) (Illumina) files in the BAM and FASTQ 
format were uploaded into Geneious R9 (Biomatters Ltd) to determine number of reads 
aligning to the mtDNA reference genome as per Genome Reference Consortium 
(GRC)h37. For FASTQ files, reads were aligned under maximal stringency to avoid 
potential multi-mapping to NUMTs (11). The number of mtDNA mapped reads was 
divided by the number of nDNA mapped reads after bioinformatic processing and 
filtering by MCS and displayed in BMS. For Supplemental Fig. 2, number reads aligning 
to Chromosome (Chr) 1 were determined in Geneious R9. Resulting values were further 
subjected to a mathematical correction factor described below. 
 
 
Precise calculation of mtDNA Score from NGS Data 
 
To calculate the mtDNA score (mNGS) for each sample using NGS, the number of reads 
mapping to the mitochondrial genome (rm) is divided by the number of reads mapping 
to the nuclear genome (rn) to normalize for technical batch-to-batch variability during 
WGA and NGS as well as number of cells collected during biopsy. The resulting value is 
multiplied by the correction factor FNGS as per formula 1. 
 
(1) ݉ேீௌ ൌ ݎ௠ݎ௡  ൈ ܨேீௌ 
 
FNGS takes into account two parameters necessary to correctly normalize for number of 
cells probed: embryo gender and ploidy. Without the correction factor, the formula 
assumes that nuclear genomes across all samples are equal in length. According to 
GRCh37 (Ensembl Release 68) the diploid female human genome is comprised of 
6,072,607,692 base pairs (bp), while the male counterpart is 5,976,710,698 bp long, a 
difference of 1.58%. Without correction, all results from male embryos are inflated by 
1.58% because the denominator rn is artificially small. To correct for this, FNGS for all 
male embryos contains a multiplier of 0.9842, since the male genome is 98.42% the 
ůĞŶŐƚŚŽĨƚŚĞĨĞŵĂůĞ ?Ɛ ?ƐĞĞdĂďůĞ ? ? ? 
 Similarly, an aneuploid embryo has more or less genetic material per cell 
compared to a euploid embryo, and without correction it would lead to inflated mtDNA 
counts in the case of nullisomies and monosomies, and deflated mtDNA counts in 
trisomies and other polysomies. To correct for this, the mtDNA value for each embryo is 
multiplied by a correction factor tailored to its chromosomal composition (Table 1A). 
The correction factors for different chromosomes should be multiplied to each other 
when embryos have aneuploidies in more than one chromosome. For example a male 
embryo with a Chr 1 monosomy and Chr 21 trisomy with 3,000 reads mapping to 
mtDNA and 900,000 reads mapping to nDNA would have the following final mNGS score: 
 ݉ேீௌ ൌ  ?ǡ ? ? ? ? ? ?ǡ ? ? ?ൈ  ሺ ?Ǥ ? ? ? ? ൈ  ?Ǥ ? ? ? ? ൈ  ?Ǥ ? ? ? ?ሻ ൌ  ?Ǥ ? ? ? ? ? ?
 
 
Determination of mtDNA content by qPCR 
 
All quantitative real time PCR (qPCR) experiments were performed using the Taqman 
system (Applied Biosystmems/Thermo Fisher). Surplus WGA product from the Veriseq 
workflow was diluted 1/10 in water, vortexed for 30-60 seconds and heated to 95 
degrees Celsius for ten minutes to insure inactivation of any residual WGA polymerase 
activity. Two microliter of the resulting solution were used in the Taqman Fast Advance 
Master Mix reaction, and run with a Taqman 7500 Real-Time PCR instrument (Applied 
Biosystems/Thermo Fisher). All samples were run in three technical replicates. Taqman 
assays CYTB (Hs02596867_s1) and ND6 (Hs02596879_g1) were used for mitochondrial 
genes, based on consistently high qPCR experimental efficiencies compared to several 
other mtDNA assays tested. An assay targeting the RNase P component RPPH1 
(Hs03297761_s1) was used for the nuclear gene; this is a routinely used copy number 
reference assay known to be present once on Chr 14 per haploid human genome (12). 
The qPCR efficiency was experimentally determined to exceed 95% for all three assays 
used in this study (Supplemental Fig. 1C-E).  Using standard curves for CYTB and RNase P 
the exact number of copies of mtDNA and nDNA was established in each sample as per 
the absolute quantitation methods described before: 
http://www6.appliedbiosystems.com/support/tutorials/pdf/quant_pcr.pdf. The ratio of 
the two values was determined and was further subjected to a correction factor 
outlined below.  
Relative quantitation of mtDNA scores was performed using the qPCR Ct values 
from ND6 as the target assay and Ct values from RNase P as the control assay, followed 
by a log-to-linear conversion (2-dCt).  
 
 
Precise Calculation of mtDNA Score from qPCR Data 
 
When using a qPCR platform, an assay is designed that probes an mtDNA region (the 
target), and second assay is designed probing a nDNA region (the reference). The 
mtDNA score (mqPCR) may be determined by absolute quantitation with a standard curve 
or relative quantitation. 
The absolute quantitation method calculates values of unknown samples by 
interpolating their quantity from a previously determined standard curve. This 
establishes an exact count of mtDNA molecules (cm) and nDNA molecules (cn) for each 
sample. Dividing the former by the latter normalizes for technical batch-to-batch 
variability as well as cell numbers collected in each biopsy. A correction factor  (FqPCR) 
must be applied to account for the nuclear genomic composition of the tested embryo, 
resulting in formula 2. 
(2) ݉௤௉஼ோ ൌ ܿ௠ܿ௡ ൈ  ܨ௤௉஼ோ 
 
FqPCR equals 1 for euploid embryos, as well as for aneuploid embryos with chromosomal 
aberrations in genetic regions other than the reference sequence. If an embryo is 
monosomic for the reference region, that emďƌǇŽ ?ƐĐĞůůƐŽŶůǇĐŽŶƚĂŝŶŽŶĞĐŽƉǇŽĨƚŚĞ
nDNA region being quantified, instead of the normal two copies. Consequently, this 
leads to cn being artificially small, which in turn inflates the mqPCR value. To correct this, 
FqPCR must include the multiplier 0.5. By extension, a trisomy of the reference sequence 
must include FqPCR with the multiplier 1.5. For example an embryo with a Chr 1 
monosomy and Chr 21 trisomy with 4x107 counts for the mtDNA target and 2x104 
counts to the nDNA reference, and the nDNA reference assay is located on Chr 21, 
would have the following final mqPCR score: 
 ݉௤௉஼ோ ൌ  ? ൈ ? ?଻ ? ൈ ? ?ସ ൈ  ሺ ?Ǥ ?ሻ ൌ  ? ? ? ? 
 
The mqPCR value represents the precise number of mtDNA molecules per nDNA 
molecules, or how many mtDNA copies there are per haploid genome. Doubling the 
value results in the number of mtDNA copies per diploid cell. 
Similarly, when using a relative quantitation qPCR mode such as 2-dCt the value 
must be adjusted if the reference assay is located in an aneuploid region, as per formula 
3. 
 
           (3) ݉௤௉஼ோ ൌ  ?ି ሺ஼௧೘ି஼௧೙ሻ ൈ ܨ௤௉஼ோ 
 
The same correction factor (see Table 1B for details) should be applied when executing 
a fold change calculation such as the 2-ddCt method (13). 
  
 
Validation of Detection Platforms  
 
Reproducibility of the NGS platform in determining mtDNA scores was tested by 
re-sequenced WGA products, which yielded consistent results amongst separate runs 
(Supplemental Fig. 1D). Also, there were unvarying mtDNA scores between multiple 
samples stemming from the same cell line with separate WGA and NGS runs. The 
starting amount of DNA for each cell line experiment was 33 pg, the equivalent DNA 
from a biopsy of 5 cells (assuming 6.6 pg per diploid genome). Furthermore, two 
separate blood samples from a single patient yielded equivalent mtDNA scores with 
individual DNA isolation, WGA and NGS procedures. 
To attain cross-platform validation, we compared the mtDNA scores of 5 embryo 
biopsy WGA samples by NGS and the two different qPCR methods described above. For 
each case the level of mtDNA score obtained by all three platforms was comparable 
(Supplemental Fig. 1E). From this data we deduce that mtDNA scores are highly 
correlative across detection platforms.  
 
 
Statistics and Graphs 
 
Group analyses were performed using tĞůĐŚ ?ƐƉĂƌĂŵĞƚƌŝĐƚǁŽ-tailed unpaired t-test in 
Prism 6 (GraphPad Software). The logistic regression analysis was performed in R 
Statistical Software. All graphs were prepared in Prism 6 showing means with error bars 





Applying Correction Factor Substantially Changes mtDNA Scores in Blastocyst Samples  
 
We analyzed mtDNA scores in blastocyst embryos used in our clinic for IVF, all of which 
had undergone routine PGS for chromosomal abnormalities. We used three distinct 
platforms to determine mtDNA and nDNA levels in a biopsy sample: NGS, qPCR by 
absolute quantitation testing for the mitochondrial gene CYTB, and qPCR by relative 
quantitation assaying for the mitochondrial gene ND6. Both qPCR methods also probed 
for the nuclear gene RNase P, which is routinely used to quantify nuclear DNA for 
normalization purposes.  
For each sample the mtDNA score was obtained by dividing the mtDNA value by 
the nDNA value to normalize for technical batch-to-batch variation and number of cells 
collected at biopsy. All resulting values were subjected to the mathematical correction 
factors that take the variability of embryonic genomes into account (See Methods for 
full explanation of the rationale and formulas).  
The NGS correction factor changed the mtDNA score on average by 1.43% +/-
1.59% (N=1396). The largest change in our samples was 17.42%. Applying the correction 
factor for qPCR changed the values by 1.33% +/-8.08% (N=150) on average when using 
the absolute quantitation method, with changes ranging up to 50.00%. When using the 
relative quantitation method, the qPCR correction factor changed mtDNA scores on 
average by 0.575% +/-5.36% (N=87), with changes ranging up to 50.00%. 
 
 
Euploid and Aneuploid Blastocysts Have Equal mtDNA Score Distributions  
 
When stratified by euploid and aneuploid blastocysts, the mtDNA scores by NGS did not 
result in a statistically significant difference (P=0.114) (Fig. 1A). Samples were randomly 
selected out of these groups and tested by qPCR absolute quantitation assaying the 
mitochondrial CYTB gene. Again, euploid and aneuploid cohorts were not statistically 
different (P=0.642) (Fig. 1B). To probe these observations by a third method, a subset of 
embryos was further assayed with different mitochondrial gene (ND6) and compared by 
a relative quantitation method (2-dCt). Once more we observed insignificant differences 
between euploids and aneuploids (P=0.202) (Fig. 1C). Therefore, regardless of 
quantitation platform and downstream mathematical calculation employed, blastocysts 
grouped by ploidy never showed statistically significant differences in mtDNA scores. 
This is in stark contrast with previous reports that did not employ a correction factor in 
their calculations (5, 6).  
 
 
Maternal Age at Oocyte Retrieval Does Not Affect mtDNA Levels of Blastocysts 
 
We divided blastocysts into a younger maternal age group at oocyte retrieval (20-37 
years) and an older group (38-46). A previous study reported a statistical difference 
stating that the older group had higher mtDNA levels (5). We investigated mtDNA scores 
by NGS amongst all embryos regardless of ploidy, and observed no difference between 
age groups (Fig. 2A). When analyzing only euploid embryos, again there was no 
significant variance (Fig. 2A). We confirmed this observation by re-testing a number of 
embryos by the two described qPCR methods, using two different mitochondrial genes 
CYTB and ND6 (Fig. 2B and 2C). We further subdivided all embryos tested by NGS by 
individual numerical maternal age at oocyte retrieval in an effort to reveal any trends, 
but linear regression analysis failed to show statistically significant tendencies (Fig. 2D 
and 2E). Hence, blastocysts derived from oocytes of advanced maternal age do not 
contain higher mtDNA levels according to our results. 
 
 
mtDNA Levels Show No Correlation with Viability and Do Not Predict Blastocyst 
Transfer Clinical Outcome  
 
We determined the mtDNA score of embryos that had undergone frozen embryo 
transfer (FET) and had either implanted or had failed to do so, as determined by the 
presence or absence of a fetal sac at 6 weeks. Biopsies from all embryos had been 
collected at the blastocysts stage. NGS data from 101 implanted and 140 not implanted 
blastocysts showed no statistical difference in mtDNA score (P=0.510) (Fig 3A).  
 With these combined 241 blastocysts we carried out a logistic regression analysis 
to investigate whether mtDNA score could function as a predictive tool for clinical 
outcomes. The test is adjusted for the following confounding factors: cohort size (i.e. 
how many embryos produced in the cycle), embryo gender, single or paired sibling 
transfer, oocyte age at retrieval, patient age at transfer, embryo stage and grade. The 
results indicate that mtDNA score is a statistically insignificant predictor embryo viability 
(P=0.472) even when adjusted for confounding factors (Supplemental Table 1).       
 In another effort to correct for confounding factors in our study, we proceeded 
to compare embryos from individual cycle cohorts. We focused on patients that had 
undergone two or more embryo transfers in our clinic within at most 12 months. For 
each patient we compared mtDNA levels between embryos that resulted in pregnancy 
versus those that failed implantation. The NGS mtDNA score of each implanting embryo 
was set to 1, and the relative mtDNA score for the non-implanted embryos was 
calculated. This normalization step allowed us to pool data from several patients into a 
single graph. Results from 24 patients show a statistically insignificant difference 
(P=0.842) between their implanted (N=25) and non-implanted (N=34) embryos (Fig. 3B). 
We repeated this analysis but in the second iteration we used uncorrected number of 
reads aligning to Chr 1 as a standardization factor. Since this particular evaluation only 
tests euploid embryos, the latter should be a valid alternative calculation method. 
Indeed, both analyses yield virtually equal results (Fig. 3B and Supplemental Fig. 2).  
Out of all the transferred embryos tested by NGS, 49 implanted and 51 not 
implanted samples were re-examined by qPCR absolute quantitation assaying for CYTB, 
again showing no statistically significant difference (P=0.103) (Fig. 3C). Finally, out of the 
latter set of blastocysts we re-tested 23 implanted and 29 not implanted embryos by 
relative quantitation (2-dCt) probing the ND6 gene, once more observing no statistical 
difference in mtDNA score between groups (P=0.145) (Fig. 3D). Two previous studies 
described an mtDNA value threshold that when surpassed served as a biomarker for 
embryos that would fail implantation (4, 5). In our data across all three detection 
systems we only observed a single sample ŝŶƚŚĞ ?ŶŽƚŝŵƉůĂŶƚĞĚ ?ŐƌŽƵƉthat repeatedly 
showed mtDNA scores substantially above the bulk distribution (see outlier in Fig. 3 A, C, 
and D), equaling 0.41% of all embryos. Hence, our data indicates that mtDNA content 
does not represent a statistically relevant or practical method to predict embryo 








Contrary to previous reports, our study finds no correlation of mtDNA content with 
blastocyst ploidy, age, or viability. While we detect a considerable range of mtDNA 
scores in the tested samples, this range is observed within all populations irrespective of 
criterion used to sub-group the blastocysts.  The absolute quantitation method by qPCR 
reveals the exact mtDNA copy number in each cell of our analyzed blastocysts. This 
value ranges from 945 to 41,427, with a mean of 4,740, falling within the previously 
estimated range of mtDNA copies per human cell (2, 14-16). 
We propose several explanations why our findings deviate from previous 
reports. Firstly, accurate determination of mtDNA levels must take the composition of 
ƚŚĞƐĂŵƉůĞ ?ƐŶƵĐůĞĂƌŐĞŶŽŵĞŝŶƚŽĂĐĐŽƵŶƚ ?/ĨŝŐŶŽƌĞĚ ?ƚŚĞĞŵďƌǇŽ ?ƐŐĞŶĚĞr and ploidy 
can substantially skew the calculated mtDNA score for a given sample. For instance 
when comparing euploids and aneuploids by NGS, if the aneuploid group randomly 
contains more monosomic than trisomic cases the overall mean of the group will be 
artificially shifted to larger mtDNA values. Also, embryos being tested by qPCR must be 
corrected when the reference assay falls in a genomic region that is aneuploid, as each 
extra or missing copy will deflate or inflate the calculated mtDNA score by a factor of 
50%. We have developed a mathematical method to accurately determine mtDNA 
scores of blastocysts that takes the genetic make-up of each sample into account. We 
propose the outlined correction factors be utilized by all laboratories investigating 
mtDNA levels whenever applicable. In addition, the outlined formulas can be used for 
mtDNA quantitation at any stage of mammalian embryology and studies of adult 
patients with aneuploidies.     
A further possible confounding factor between studies is that both previously 
published reports on embryo viability originate from reference laboratories that 
collected data from numerous centers, agglomerating all their numbers (4, 5). As a 
result, it is unclear whether their findings hold true individually within all the different 
clinics. Ours is the first investigation stemming from a single center, thereby correcting 
for several potential inter-facility variables such as culture media, temperature, biopsy 
technique, or equipment. Furthermore, we have amassed a number of samples 
unprecedented to date for this type of study in the published literature. 
Lastly, It should be noted that previous reports on mtDNA levels, aside from 
showing interesting concordances, also show several discrepancies amongst them. For 
instance Fragouli et al (5) suggest a maternal age effect, while Diez-Juan et al (4) did not 
see a maternal age correlation. Secondary analysis of the data in Tan et al (6) also shows 
no age effect.  Furthermore, Diez-Juan et al describes a viability effect in cleavage and 
blastocyst stage embryos, while Fragouli et al only detects it in blastocysts and not at 
the cleavage stage. These divergences remain to be explained and possibly point 
towards a technical or laboratory-specific effect.  
The qPCR analysis in Diez-:ƵĂŶ ?Ɛreport relies on a single copy locus to normalize 
for nDNA, like our study. Fragouli et al utilize a multicopy Alu sequence, with the 
rationale that allele-drop-out (ADO) effects during WGA might be mitigated. In the 
context of blastocysts, where a 5-10 cell biopsy yields 10-20 initial copies of a single 
copy locus (in euploids), use of a multicopy sequence is unlikely to confer an advantage. 
The maximal estimated ~10% ADO (17) using the routinely employed Sureplex WGA 
system (Rubicon) would affect the initial 10-20 single locus copies or a multicopy 
sequence in a similar manner. Furthermore, there is well-documented variability in Alu 
sequence frequencies and compositions within the population (18-20), leading us to 
believe that a known single-copy locus such as RNAseP (12) is a superior method of 
standardization between embryos. Nevertheless, the potential for ADO error persists in 
our study as well. Another important limitation is that our NGS protocol does not permit 
differentiation between embryos with homogenously haploid, diploid, triploid, etc. 
genomes.                
The Quiet Embryo Hypothesis postulates that an embryo with a calm metabolic 
state is more viable than another with an overactive metabolism (7). While we find no 
association between mtDNA content and embryonic stress, our data does not refute the 
proposed concept that embryos actively increase mitochondrial function and energy 
output as a compensatory response to overcome strained conditions. The number of 
mtDNA copies per mitochondrion in human cells can vary widely between 0 to 15 (21-
23), meaning that the number of mtDNA copies per cell does not necessarily correlate 
to number of mitochondrial organelles. At least one report has demonstrated that 
mtDNA copy is a poor biomarker for mitochondrial content (24). Different techniques 
such as immunofluorescence for direct organelle quantitation or chemical ATP detection 
would yield a clearer picture of mitochondrial number and function in embryos, which in 
turn could prove to be valid biomarkers for embryo viability.  
We find an interesting historical parallel to this narrative. Within the context of 
the mammalian oocyte, initial studies reported that mtDNA levels might serve as a 
predictive biomarker for implantation (25-28), but later reports rebutted these findings 
(2, 29, 30). Time and further studies will tell if history repeats itself, this time from the 
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Figure 1. mtDNA scores sorted by euploid and aneuploid blastocysts result in statistically 
insignificant differences. (A) Next Generation Sequencing (NGS) data. (B) Quantitative 
RT-PCR (qPCR) data probing for a locus in the CYTB mitochondrial gene analyzed by 
absolute quantitation. (C) qPCR data probing for a locus in the ND6 mitochondrial gene 




Figure 2.  mtDNA scores of blastocysts sorted by maternal age at the time of oocyte 
retrieval. (A) NGS data sorted by two age groups (20-37 and 38-46) analyzing all 
embryos and euploids alone, indicating no relevant differences. (B-C) mtDNA scores 
derived by the two described alternative qPCR methods showing no significant 
differences. (D-E) NGS values sorted by individual age, evaluating all embryos and 
euploids alone. Insets show linear regression through the means, resulting in statistically 
insignificant P values. N. S. = not significant. 
 
 
Figure 3. mtDNA scores and implantation potential of transferred euploid blastocysts.  
(A) NGS data from all transferred blastocysts shows no statistically significant difference. 
(B) Intra-cohort analysis for 24 patients with repeat transfers results in insignificant 
differences. (C-D) Statistically insignificant differences resulting from absolute and 
relative quantitation qPCR probing two different mitochondrial genes CYTB and ND6, 
respectively. Only ŽŶĞƐĂŵƉůĞŝŶƚŚĞ ?ŶŽƚŝŵƉůĂŶƚĞĚ ?ŐƌŽƵƉĐŽŶƐŝƐƚĞŶƚůǇƐŚŽǁs an 
mtDNA score above a possible threshold across platforms. N. S. = not significant. 
 
 
Supplemental Figure 1. (A-C) Standard curves for the three qPCR assays used, showing 
high experimental efficiency. (D) NGS validation for mtDNA score reproducibility. 
Blastocyst biopsy-derived WGA samples were sequenced in duplicates (full circles) or 
triplicates (full diamonds) showing consistent mtDNA scores in repeated runs. Each 
sample from a-l represents one embryo WGA biopsy and numbers represent number of 
replicate NGS runs. Cell samples from two different cell lines (m and n) underwent 
repeated WGA and subsequent NGS. Half circles represent two replicates for cell line m, 
and half squares represent four replicates for cell line n. The consistent values for each 
cell line indicate that neither WGA nor NGS introduce variability in the mtDNA score 
determination. Full triangles (o) depict a duplicate run of blood isolated from a patient, 
for which DNA isolation, WGA, and NGS were run separately, and resulted in consistent 
mtDNA scores. (E) WGA samples from five blastocysts (Controls A-E) were used to 
determine mtDNA scores by NGS (purple circles), qPCR assaying the mitochondrial CYTB 
gene by absolute quantitation (blue circles), and qPCR assaying the mitochondrial ND6 
gene by relative quantitation (orange circles). Raw values for each technique (indicated 
above the circles) were normalized to Control A. Fold changes of mtDNA scores 
A<B<C<D<E for all three techniques, indicating cross-platform consistency of mtDNA 
score ranking.  
 
 
Supplemental Figure 2.  Intra-cohort analysis of mtDNA scores for 24 patients with 
repeat transfers sorted by blastocyst viability, showing a statistically insignificant 
difference. For this NGS analysis only reads aligning to Chr 1 were used for 
standardization. N. S. = not significant. 
 
